Biohaven Pharmaceutical Holding Company Ltd.
BHVNNext catalyst
BHV-7000
Bipolar Disorder
Get an email about BHVN's next catalysts
Track Biohaven Pharmaceutical Holding Company (BHVN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 0 past
BHVN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.80 | FQ end Sep/2026 | Call: tbd
BHV-7000 Phase 3 Est. Readout (RISE 2)
Primary completion for BHV-7000 trial (NCT06132893) in Focal Epilepsy
SourceBHV-8000 Phase 3 Est. Readout
Primary completion for BHV-8000 trial (NCT06976268) in Parkinson Disease
SourceHow BHVN's past catalysts played out
Market Overview
Stock performance and key metrics
BHV-0223
Social Anxiety Disorder
Taldefgrobep Alfa
Obesity
BHV-8000
Parkinson Disease
BHV-7000
Bipolar Disorder
Verdiperstat
Multiple System Atrophy
troriluzole
Spinocerebellar Ataxias
BHV-2100
Migraine
BHV-1510
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BHV-0223 | Phase 3 | Social Anxiety Disorder | - | - |
Taldefgrobep Alfa | Phase 3 | Obesity | - | - |
BHV-8000 | Phase 3 | Parkinson Disease | - | - |
BHV-7000 | Phase 3 | Bipolar Disorder | - | - |
Verdiperstat | Phase 3 | Multiple System Atrophy | - | - |
troriluzole | Phase 3 | Spinocerebellar Ataxias | - | - |
BHV-2100 | Phase 2 | Migraine | - | - |
BHV-1510 | Phase 2 | Solid Tumor | - | - |
epilepsy
2 drugs in this indication
depression
1 drug in this indication
Graves' Disease
1 drug in this indication
focal epilepsy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Biohaven Pharmaceutical Holding Company Ltd.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) pipeline across Phase 3, Phase 2. Its lead program is BHV-7000 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biohaven Pharmaceutical Holding Company Ltd.'s next FDA catalyst?→
Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BHVN biotech catalysts?→
Add BHVN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biohaven Pharmaceutical Holding Company Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.